Histologic grade is an independent prognostic factor for survival in non–small cell lung cancer: An analysis of 5018 hospital- and 712 population-based cases  by Sun, Zhifu et al.
H
s
h
Z
B
General Thoracic Surgery Sun et al
1
G
TSistologic grade is an independent prognostic factor for
urvival in non–small cell lung cancer: An analysis of 5018
ospital- and 712 population-based cases
hifu Sun, MD, MS,a Marie-Christine Aubry, MD,b Claude Deschamps, MD,c Randolph S. Marks, MD,d Scott H. Okuno, MD,drent A. Williams, MS,e Hiroshi Sugimura, MD,a V. Shane Pankratz, PhD,e and Ping Yang, MD, PhDa
O
c
M
7
t
p
a
a
R
f
t
r
t
s
t
i
p
t
r
(
p
C
p
i
i
L
o
o
a
r
T
s
c
P
c
pFrom the Divisions of Epidemiology,a Ana-
tomic Pathology,b Thoracic Surgery,c Med-
ical Oncology,d and Biostatistics,e Mayo
Clinic College of Medicine, Rochester, Minn.
This study was supported by the US Na-
tional Cancer Institute (grants CA80127
and CA84354 to Dr Yang) and Mayo Foun-
dation Funds.
Received for publication Sept 29, 2005;
revisions received Dec 21, 2005; accepted
for publication Dec 30, 2005.
Address for reprints: Ping Yang, MD, PhD,
Mayo Clinic, Department of Health Sciences
Research, 200 First Street SW, Rochester,
MN 55905 (E-mail: yang.ping@mayo.edu).
J Thorac Cardiovasc Surg 2006;131:1014-20
0022-5223/$32.00
Copyright © 2006 by The American Asso-
ciation for Thoracic Surgerys
doi:10.1016/j.jtcvs.2005.12.057
014 The Journal of Thoracic and Cardbjective: Our objective was to determine whether histologic grade independently
ontributes to the prognosis of non–small cell lung cancer.
ethods: A total of 5018 hospital-based patients diagnosed from 1997 to 2003 and
12 population-based patients diagnosed from 1984 to 2003 were followed up
hrough the end of 2004. The effect of histologic grade on postdiagnosis survival or
ostresection recurrence was evaluated by Cox proportional hazards models. Rel-
tive risks (RR) were estimated by comparing undifferentiated, poorly differenti-
ted, and moderately differentiated carcinoma with well-differentiated carcinoma.
esults: Histologic grade was significantly associated with survival after adjustment
or the effects of age, gender, smoking history, tumor stage, histologic cell type, and
reatment modality. Patients with undifferentiated carcinoma had an 80% elevated
isk of death (RR  1.83; 95% confidence interval [CI], 1.4-2.4) compared with
hose with well-differentiated carcinoma; 70% and 40% elevated risks were ob-
erved for patients with poorly and moderately differentiated carcinoma, respec-
ively (RR, 1.7 [1.5-2.0] and 1.4 [1.2-1.6]). Similar results were observed for 718
ncidence cases in which the relative risks were 1.6 (1.1-2.2) and 1.4 (1.0-1.9) for
oorly/undifferentiated carcinoma and moderately differentiated carcinoma, respec-
ively. Patients with less-differentiated carcinoma after tumor resection had a higher
isk of recurrence, with adjusted hazard ratios of 2.1 (95% CI: 1.4-2.9) and 1.4
1.0-1.9) for poorly/undifferentiated and moderately differentiated carcinoma com-
ared with well-differentiated carcinoma.
onclusions: Histologic grade has significant prognostic value for survival of
atients with non–small cell lung cancer. Histologic grade may provide useful
nformation in defining the aggressiveness of tumors and should be considered as an
ndependent factor affecting survival beyond TNM staging.
ung cancer is the leading cause of cancer death for both men and women in the
United States and many regions of the world.1 Only a few prognostic factors
have been established for assisting patient management and predicting clinical
utcome. For non–small cell lung cancer (NSCLC), histologic grading is routinely based
n the degree of tumor cell differentiation and reported along with the histologic subtype
nd other information (tumor size, margin, and lymph node involvement). However, the
ole of histologic grade as a prognostic factor has rarely been systematically evaluated.
he correlation of histologic grade with cancer prognosis was first described for
quamous cell carcinoma of the skin by Broders2 in 1920 and later was found in
arcinomas of many other organs, such as the rectum, breast, kidney, and prostate.
atients with high-grade disease more often had a higher stage at diagnosis, a greater
hance of recurrence or metastasis, and a shorter survival time after diagnosis. The
redictive value of histologic grade prompted the development of specific grading
ystems for some tumors, such as Gleason’s2a grading for prostate carcinoma,
iovascular Surgery ● May 2006
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G
TSurhman’s2b grading for renal cell carcinoma, and Elston’s2c
rading for breast carcinoma. A similar phenomenon has not
een observed with lung cancer, mostly due to the controver-
ial results of earlier studies, likely as a result of tumor heter-
geneity, short and variable survival, and small sample sizes,
hich precluded multivariate analysis. To answer the question
hether histologic grade has an independent impact and to
hat extent, if any, on the prognosis of NSCLC, we have
nalyzed data from a large patient population diagnosed with
SCLC from Mayo Clinic in Rochester, Minnesota.
ethods
tudy Population
rom January 1, 1997, to December 31, 2003, we prospectively
nrolled 5018 patients with pathologically proven NSCLC (excluding
arcinoid and salivary gland tumors) at Mayo Clinic, Rochester,
innesota. Detailed procedures of patient enrollment, diagnosis, data
ollection, and follow-up have been described in previous publica-
ions.3,4 Histologic classification was made according to the World
ealth Organization’s International Histological Classification of Tu-
ors current at the time of diagnosis and TNM stage as proposed by
ountain5 in 1997. Histologic grade was evaluated by the patholo-
ists at Mayo Clinic and categorized as follows: well differentiated,
oderately differentiated, poorly differentiated, and undifferentiated.
full medical record abstraction was conducted to obtain demo-
raphics, history of tobacco exposure, lung cancer pathologic type,
linical staging, and treatment. All patients were actively followed up
eginning 6 months after diagnosis, with subsequent annual follow-up
y mailed questionnaires. Timely verification of patients’ vital status
as of December 31, 2004) was accomplished through the Mayo
linic’s electronic clinical notes and registration database, next-of-kin
eports, death certificates, and obituary documents filed in the pa-
ients’ medical records, as well as through the Mayo Clinic Tumor
egistry and Social Security Death Index website.
Our second study population was patients diagnosed with
SCLC from Olmsted County, Minnesota, where Mayo Clinic is
ocated. Virtually all Olmsted County residents seek medical care
t Mayo Clinic, where each lung cancer case has been identified
nd followed since 1984. A total of 712 NSCLC patients were
nrolled by the end of 2003. We used this cohort to evaluate the
otential referral bias of histologic grade effect on survival. All
atients in this study were authorized for research and contact
aterials were reviewed and approved by the Mayo Foundation
nstitutional Review Board.
tatistical Analysis
he primary outcome in this analysis was survival after a lung
ancer diagnosis. Survival was defined as the years from lung
Abbreviations and Acronyms
CI  confidence interval
NSCLC non–small cell lung cancer
RR  relative riskancer diagnosis to death or the last known date alive. Patients l
The Journal of Thoracicnown to be alive at last contact were censored. Tumor distribution
mong well-differentiated, moderately differentiated, poorly dif-
erentiated, and undifferentiated carcinoma was tabulated by age,
ender, histologic type, stage, smoking history, and treatment. The
ssociation of each variable with histologic grade was assessed by a
hi-square test for categorical variables and an analysis of variance for
ontinuous variables. Univariate association of age at diagnosis,
ender, smoking history, stage, histologic cell type, histologic
rade, and treatment with survival was evaluated by the Kaplan-
eier method.6 To evaluate the independent role of histologic
rade on survival, a multivariate Cox proportional hazards model6
as applied to include all above-mentioned variables and adjusted
elative risks (RR) were estimated. Because treatments were not
ssigned at random, we also adjusted for propensity scores that
eflected the probabilities that an individual would be assigned a
iven treatment modality. These scores were generated by logistic
egression models7 that used all available covariates to predict the
robability of each possible treatment combination. This resulted
n 8 different propensity scores, which we classified into tertiles to
valuate differences within treatment propensities.8 Indicator vari-
bles for these propensity score groupings were included in the
ox proportional hazards regression models, and separate Cox
odels were fit to the data, stratified by each of the treatment-
pecific propensity categorizations.
Since no significant difference between undifferentiated carci-
oma and poorly differentiated carcinoma was observed in the
verall regression model, we combined the two grades into a single
roup (poorly/undifferentiated carcinoma) in the downstream
tratified and subset analyses. The impact of histologic grade on
ostdiagnosis survival was further assessed by estimating the RR
f death stratified on gender, stage, histology, and treatment.
nteractions between histologic grade and each of these variables
ere tested. The same analytical approaches were applied to the
lmsted County patients, and the same adjustment variables were
ncluded in the Cox model.
Because the main cause of cancer death after curative surgery
s tumor recurrence, we evaluated what role histologic grade had
n tumor recurrence by analyzing data of 1302 NSCLC patients
iagnosed from 1997 to 2001 who received curative resection and
ad complete recurrence information.9 We used the Cox propor-
ional hazards model with the time to recurrence after surgery as an
vent. Risk of recurrence was evaluated among three histologic
rades after adjustment for age at diagnosis, gender, histologic cell
ype, tumor stage, and adjuvant therapies (chemotherapy and/or
adiation therapy).
All analyses were performed with SAS software, version 8.2
SAS Institute, Cary, NC). Adjusted survival curves were created
y the optimal corrected group prognosis method as described by
hali and associates.10
esults
asic Characteristics and Univariate Analysis
ge, gender, smoking history including pack-years smoked
nd time after smoking cessation, tumor stage, histologic
ell type, and treatment modality varied significantly with
istologic grade (Table 1). Younger patients were more
ikely to have poorly or undifferentiated carcinoma. Men
and Cardiovascular Surgery ● Volume 131, Number 5 1015
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G
TSad a higher proportion of poorly or undifferentiated carci-
oma than women did. Never smokers had a higher propor-
ion of well-differentiated carcinoma than of moderately,
ABLE 1. Demographic and clinical characteristics of 501
haracteristics
Well-
differentiated
(n  668)
ge, y (mean) 67
50 56, 8.4%
50 and 65 208, 31.1%
65 and 80 350, 52.4%
80 54, 8.1%
ender
Male 331, 49.6%
Female 337, 50.5%
moking history
Never 139, 20.9%
Past 367, 55.3%
Current 158, 23.8%
Unknown 4
moking pack-years
None 139, 23.5%
0-20 93, 15.7%
20-40 133, 22.5%
40-60 113, 19.1%
60 113, 19.1%
Unknown 77
uit years (former smokers)
0-10 128, 39.9%
10-20 80, 24.9%
20-30 59, 18.4%
30 54, 16.8%
tage
I 372, 55.9%
II 39, 5.9%
III 113, 17.0%
IV 141, 21.2%
Unknown 3
istologic cell type
Adenocarcinoma 571, 85.5%
Squamous 96, 14.4%
Large cell 0
Adenosquamous 1, 0.2%
Unspecified NSCLC 0
Sarcomatoid 0
reatment
Surgery only 417, 63.6%
Chemotherapy only 61, 9.3%
Radiation only 17, 2.6%
Surgery  radiation 10, 1.5%
Surgery  chemotherapy 21, 3.2%
Chemotherapy  radiation 39, 6.0%
Surgery  chemotherapy radiation 19, 2.9%
None 72, 11.0%
Unknown 12oorly, or undifferentiated carcinoma. Conversely, heavy s
016 The Journal of Thoracic and Cardiovascular Surgery ● Mamokers or smokers who quit within a short time of cancer
iagnosis had more poorly or undifferentiated carcinoma.
ost well-differentiated carcinomas were seen in earlier
CLC patients
derately
rentiated
 2111)
Poorly
differentiated
(n  1410)
Undifferentiated
(n  829) P value
66 65 65 .001
68, 8.0% 168, 11.9% 99, 11.9% .001
2, 36.1% 496, 35.2% 289, 34.9%
3, 49.9% 661, 46.9% 373, 45.0%
28, 6.1% 85, 6.0% 68, 8.2%
5, 59.0% 857, 60.8% 498, 60.1% .001
6, 41.0% 553, 39.2% 331, 40.0%
8, 11.0% 151, 10.9% 74, 9.2% .001
1, 57.2% 717, 51.7% 408, 50.7%
4, 31.9% 518, 37.4% 323, 40.1%
28 24 24
8, 13.0% 152, 13.2% 74, 10.9% .001
1, 11.4% 127, 11.0% 86, 12.6%
8, 23.2% 267, 23.2% 178, 26.1%
2, 25.7% 297, 25.8% 171, 25.1%
0, 26.7% 309, 26.8% 173, 25.4%
352 258 147
9, 48.2% 308, 53.8% 196, 57.7% .001
8, 25.5% 135, 23.6% 64, 18.8%
9, 16.3% 78, 13.6% 52, 15.3%
8, 10.1% 52, 9.1% 28, 8.2%
1, 30.7% 204, 14.6% 91, 11.3% .001
5, 10.8% 120, 8.6% 42, 5.2%
8, 29.6% 514, 36.9% 243, 30.0%
3, 28.9% 555, 39.8% 433, 53.5%
24 17 20
4, 57.0% 823, 58.4% 0 .001
6, 41.5% 439, 31.1% 0
0 23, 1.6% 149, 18.0%
31, 1.5% 117, 8.3% 0
0 8, 0.6% 644, 77.7%
0 0 36, 4.3%
6, 42.6% 344, 25.0% 98, 12.3% .001
02, 9.7% 216, 15.7% 168, 21.0%
51, 7.3% 141, 10.2% 126, 15.8%
94, 4.5% 47, 3.4% 15, 1.9%
81, 3.9% 48, 3.5% 26, 3.3%
4, 13.7% 277, 20.1% 182, 22.8%
26, 6.1% 57, 4.1% 28, 3.5%
7, 12.4% 248, 18.0% 156, 19.5%
30 32 308 NS
Mo
diffe
(n
1
76
105
1
124
86
22
119
66
22
20
40
45
47
46
24
15
9
64
22
61
60
120
87
88
2
1
28
1tages (I and II), and the majority of poorly or undifferen-
y 2006
t
W
n
m
w
a
s
n
s
8
(
t
c
C
s
e
1
w
u
a
w
d
c
w
c
m
c
(
M
A
h
u
s
(
c
e
1
t
c
1
r
u
f
C
i
w
p
d
a
c
t
7
i
s
t
r
c
w
(
u
d
Sun et al General Thoracic Surgery
G
TSiated carcinomas were found in the later stages (III and IV).
ell-differentiated carcinomas were mostly adenocarci-
oma. Patients with well-differentiated carcinoma had a
uch higher chance of being treated surgically than patients
ith poorly or undifferentiated carcinoma.
Stage, histologic cell type, histologic grade, treatment, age,
nd gender were all significantly associated with post diagnosis
urvival (P  .001). However, smoking history was not sig-
ificant (P  .2). For histologic grade, the estimated crude
urvival at 1 and 5 years in well-differentiated carcinoma was
0.5% (95% confidence interval [CI]: 77.5-83.6) and 43.5%
95% CI: 39.0-48.6), respectively, with a median survival
ime of 3.7 years. The survival for moderately differentiated
arcinoma was 65.5% (95% CI: 63.5-67.6) and 23.4% (95%
I: 21.2- 25.8) at 1 and 5 years, respectively, with a median
urvival time of 1.7 years. The survival for poorly differ-
ntiated carcinoma was 47.7% (95% CI: 45.1-50.4) and
3.4% (95% CI: 11.5-15.7) at 1 and 5 years, respectively,
ith a median survival time of 0.9 year; and the survival for
ndifferentiated carcinoma was 40.0% (95% CI: 36.7-43.6)
nd 8.3% (95% CI: 6.2-11.2) at 1 and 5 years, respectively,
ith a median survival time of 0.8 year. The RR of post-
iagnosis mortality among patients with undifferentiated
arcinoma versus those with well-differentiated carcinoma
as 3.5 (95% CI: 3.1-4.0); between poorly differentiated
arcinoma and well-differentiated carcinoma and between
oderately differentiated carcinoma and well-differentiated
arcinoma, the RRs were 2.7 (95% CI: 2.4-3.1) and 1.8
95% CI: 1.6-2.0), respectively (Figure 1, A).
ultivariate Analysis
fter adjustment for age at diagnosis, tumor stage, gender,
 Kaplan-Meier Survival Curves for 5018 NSCLC Patients
by Histologic Grade
0
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Figure 1. A, Crude survival curves by histologic grade
all patients after adjustment for age, gender, smoking h
Relative risk, compared with well-differentiated carcin
different from moderately differentiated carcinoma (Pistologic cell type, smoking history, and treatment with the w
The Journal of Thoracicse of a multivariate Cox proportional hazard model, survival
till differed significantly among the four histologic grades
Table 2, Figure 1, B). Compared with well-differentiated
arcinoma, undifferentiated, poorly, and moderately differ-
ntiated carcinomas had RRs of 1.8- (95% CI: 1.4-2.4),
.7- (95% CI: 1.5-2.0) and 1.4-fold (95% CI: 1.2-1.6), respec-
ively. The RRs of undifferentiated and poorly differentiated
arcinoma over moderately differentiated carcinoma were
.3- (95% CI: 1.0-1.6) and 1.2-fold (95% CI: 1.1-1.3),
espectively. However, the increased risk of mortality for
ndifferentiated carcinomas was not significantly different
rom that of poorly differentiated carcinomas (RR: 1.1, 95%
I: 0.9-1.3). The two grades were combined in the follow-
ng subset analyses to reduce the data sparsity. In addition,
e found that histologic grade was the third most significant
rognostic factor, following tumor stage and treatment mo-
ality. Tumor histologic cell type and patient gender were
lso confirmed to be predictors of survival.
The factors used in this regression model were asso-
iated with treatment modality, with concordance be-
ween predicted and observed treatments ranging from
0% to 90% for the 8 treatment combinations. Adding
ndicator variables representing tertiles of these propen-
ity scores for all 8 treatment modalities to the propor-
ional hazards model made little difference in the hazard
atio estimates. On average, however, they slightly in-
reased the risk estimates of higher histologic grades,
ith hazard ratios of 1.91 (95% CI: 1.40-2.60), 1.82
95% CI: 1.51-2.20), and 1.46 (95% CI: 1.21-1.77) for
ndifferentiated, poorly differentiated, and moderately
ifferentiated carcinoma, respectively, compared with
 Adjsuted Survival Curves for 5018 NSCLC Patients
by Histologic Grade
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).S
u
rv
iv
al
 F
u
n
ct
io
n
B
for a
istor
oma;
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1
G
TStratified Analysis (Table 3)
hen stratified by tumor stage, the unfavorable impact of
ess-differentiated carcinoma on survival was observed in all
tages except for stage II, where the effect size (RR 1.7 and
.5) was similar to other stages but had wider 95% CIs over-
apping with unity. Poorly/undifferentiated and moderately
ifferentiated stage I carcinomas had a 51% and 34% increased
ABLE 2. Histologic grade effect on survival of NSCLC
djusted for age, gender, smoking status, stage, histologic
ell type, and treatment with comparison of their relative
ignificance
actors
Hazard
ratio 95% CI P value
tage
Stage I 1 — —
Stage II 1.66 1.42, 1.94 .001
Stage III 2.21 1.94, 2.53 .001
Stage IV 3.28 2.86, 3.76 .001
reatment
Surgery 1 — —
Surgery  chemotherapy 1.20 0.97, 1.49 .09
Surgery  chemotherapy 
radiation
1.25 1.04, 1.51 .02
Surgery  radiation 1.66 1.35, 2.01 .001
Chemotherapy 2.60 2.25, 3.00 .001
Radiation 3.58 3.07, 4.17 .001
No treatment 4.02 3.51, 4.59 .001
istologic grade
Well differentiated 1 — —
Moderately differentiated 1.41 1.24, 1.61 .001
Poorly differentiated 1.71 1.49, 1.95 .001*
Undifferentiated 1.83 1.42, 2.36 .001*†
istologic cell type
Squamous 1 — —
Large cell 0.85 0.63, 1.16 .30
Adenosquamous 0.93 0.66, 1.32 .68
Unspecified NSCLC 0.93 0.74, 1.15 .49
Adenocarcinoma 0.92 0.84, 1.00 .04
Sarcomatoid 1.56 1.03, 2.34 .04
ge
50 1 — —
50  and 65 0.92 0.81, 1.04 .20
65  and 80 1.25 1.11, 1.41 .001
80 1.44 1.21, 1.71 .001
ender
Female 1 — —
Male 1.25 1.17, 1.35 .001
moking history
Nonsmokers 1 — —
Former smokers 1.09 0.97, 1.23 .13
Current smokers 1.13 1.00, 1.28 .05
Also significant when compared with moderately differentiated carcinoma.
Not significantly different from poorly differentiated carcinoma.isk of death, respectively, compared with well-differentiated a
018 The Journal of Thoracic and Cardiovascular Surgery ● Maarcinoma. The excess risk of mortality was 90% and 48% for
tage IV carcinomas, respectively.
When stratified by histologic cell type, the patients with
oorly/undifferentiated and moderately differentiated adeno-
arcinoma had a 70% and 41% increased risk of death com-
ared with patients with well-differentiated adenocarcinoma,
espectively. The elevated risk of mortality for patients with
quamous cell carcinoma was 53% and 34% for poorly/
ndifferentiated carcinoma and moderately differentiated
arcinoma, respectively.
Regardless of treatment modalities, moderately differenti-
ted or poorly/undifferentiated carcinoma added a 35% to 83%
isk of mortality compared with well-differentiated carcinoma.
ubgroup Analysis for Olmsted County Patients
hen compared with well differentiated carcinoma, the unad-
usted RRs for poorly/undifferentiated carcinoma and moder-
ABLE 3. Stratified analyses of histologic grade on sur-
ival by gender, stage, histologic cell type, and treatment
Moderately
differentiated*
RR,† P value
(95% CI)
Poorly/
undifferentiated*
RR,† P value
(95% CI)
ender
Male (n  2931) 1.48,.001 1.78, .001‡
(1.25, 1.76) (1.49, 2.13)
Female (n  2087) 1.35, .003 1.65,.001‡
(1.11, 1.65) (1.34, 2.04)
tage
Stage I (n  1308) 1.34, .02 1.51, .01
(1.05, 1.73) (1.11, 2.06)
Stage II (n  426) 1.45, .17 1.72, .06
(0.85, 2.45) (0.99, 2.98)
Stage III (n  1488) 1.24, .09 1.45, .004‡
(0.97, 1.59) (1.13, 1.86)
Stage IV (n  1732) 1.48, .001 1.90,.001‡
(1.19, 1.84) (1.53, 2.37)
istologic cell type
Squamous (n  1411) 1.34, .04 1.53, .004
(1.01, 1.76) (1.15, 2.05)
Adenocarcinoma (n  2598) 1.41,.001 1.70, .001‡
(1.21, 1.64) (1.45, 1.99)
reatment
Surgery only (n  1745) 1.43, .002 1.63,.001
(1.14, 1.79) (1.26, 2.11)
Chemotherapy and/or
radiation (n  1864)
1.50,.001
(1.20, 1.88)
1.83, .001‡
(1.46, 2.30)
No treatment (n  733) 1.35, .04 1.51, .01
(1.01, 1.80) (1.13, 2.03)
The reference is well-differentiated carcinoma. †RR, Relative risk ad-
usted for age, gender, smoking history, histologic cell type, stage, and
reatment. ‡Also significant at P  .05 level compared to moderately
ifferentiated carcinoma.tely differentiated carcinoma were 3.0 (95% CI: 2.2-4.0) and
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G
TS.9 (95% CI: 1.4-2.5), respectively. The adjusted RR for poorly/
ndifferentiated carcinoma was 1.6 (95% CI: 1.2-2.2) and for
oderately differentiated carcinoma, 1.4 (95% CI: 1.0-1.9),
uggesting that the independent role of histologic grade on
urvival in NSCLC was less likely inflated by patient referral
n the tertiary hospital setting.
istologic Grade Is Associated With Tumor
ecurrence After Surgery
mong 1302 surgically treated patients with complete re-
ection, those with poorly/undifferentiated, moderately dif-
erentiated, and well-differentiated carcinoma had recur-
ence rates of 47.3%, 32.7%, and 20.8%, respectively. After
djustment for age at diagnosis, gender, histologic cell type,
umor stage, and adjuvant therapies, patients with poorly/
ndifferentiated carcinoma had a 2.1-fold increased risk
hazard ratio: 2.1; 95% CI: 1.4-2.9) of cancer recurrence
ompared with well-differentiated carcinoma. For patients
ith moderately differentiated carcinoma, the increased risk
f recurrence was 1.4-fold (95% CI: 1.0-1.9). These results
rovided additional evidence that less-differentiated tumors
ere independently associated with a higher risk of recur-
ence and offered a possible explanation for a shortened
verall survival.
onclusions
n our study, we focused on the role of histologic grade on
urvival of NSCLC. Histologic grade was shown to be a
ignificant prognostic factor. Similar results were observed
n a cohort of patients from a single county, suggesting that
he results obtained from the large cohort were unlikely to
e biased by patient referral. No significant difference on
urvival was observed between undifferentiated carcinoma and
oorly differentiated carcinoma. Less-differentiated carci-
oma was associated with a higher risk of tumor recurrence
fter complete tumor resection.
In the literature, the role of histologic grade as a prognostic
actor in lung cancer is controversial. Similar to our findings, in
n analysis of 96 patients with lung cancer, Chung and asso-
iates11 found that poorly differentiated tumors had higher
ates of lymph node metastasis and local recurrence as well as
horter survival than did well- or moderately differentiated
umors. However, the results were obtained mostly by univar-
ate analyses, and the independent role of histologic grade was
ot assessed because of the limited sample size. In one of a few
tudies using multivariate adjustment, Ichinose and cowork-
rs12 found histologic grade was a significant predictor for
esected stage I tumors but did not have any impact on stage II
nd stage IIIA tumors. Noted in their study, the numbers of
atients in stage II and IIIA were only 63 and 108, respec-
ively, which were far less than the 243 patients in stage I.12
isparate survival was also reported in early-stage resected
denocarcinoma13 or in late-stage nonresectable adenocarci-
oma treated with chemotherapy and/or radiation therapy.14 r
The Journal of Thoracicevertheless, many studies have not found an independent role
f histologic grade in lung cancer survival or did not even
nclude it in their survival analyses.15-18 The diverse results are
ikely due to several factors: (1) Sample sizes are generally
mall, which may not be able to detect moderate predictive
ffects. (2) Since NSCLC is a very heterogeneous group of
umors, the effect of histologic grade on survival may differ
mong different cell types or treatment modalities and results
btained from one subset of patients with lung cancer may not
e same as others. (3) Inconsistent grading criteria among
athologists and different grouping systems among grades in
nalysis (eg, well- and moderately differentiated combined
ersus moderately and poorly differentiated combined) may
lso contribute to varied results. In our study, we have tried to
ddress all the points listed above; however, inconsistent grad-
ng criteria may remain an issue.
A challenge of evaluating histologic grade is that the
resent grading system for lung cancer is not standardized. A
our-tiered system of grading ranging from well-differentiated,
oderately differentiated, poorly differentiated, and undiffer-
ntiated carcinoma is suggested for most cancers, including the
ung, in the American Joint Committee on Cancer Staging
andbook19 and World Health Organization Histological
yping of Lung and Pleural Tumors,20 but no specific
riteria have been developed for a universal assessment in
ung cancer. Usually, histologic grade is based on the per-
entage of tumor differentiation and other features, such as
pecific growth patterns, cytologic atypia, and mitotic rates.
n this study, histologic grade was obtained mostly from the
outine readings of the pathologists at Mayo Clinic follow-
ng the general guidelines, but no centralized slide review
as conducted owing to lack of a universally accepted
gold standard” to follow. With the findings from this study,
urther investigation and development of a systematic grad-
ng system for a unified assessment is warranted to help
etter define prognostic subgroups.
The results of this study have several implications: (1)
istologic grade has a significant impact on survival of pa-
ients with NSCLC; the impact is the third most important after
umor stage and treatment modality and is independent of other
nown predictors. However, similar results may not be ob-
ained from a limited number or restricted subset of patients in
he context of high complexity and heterogeneity of NSCLC,
s reported in the literature. (2) With the development of new
echnologies, our current search for determinants of NSCLC
urvival has been focusing on the molecular level. For exam-
le, gene expression profiling using microarray analysis may
rovide more accurate classification of NSCLC21,22 and better
rediction for survival.23,24 However, the markers or signatures
dentified from that approach have been rarely evaluated along
ith other key prognostic factors such as tumor stage and
istologic grade, and it is not clear whether those markers are
elated to histologic grade. If histologic grade is proven prog-
and Cardiovascular Surgery ● Volume 131, Number 5 1019
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G
TSostic, our search for new promising markers needs to focus on
hose that can provide additional value beyond histologic grade
r can provide accurate measurement of histologic grade. (3)
istologic grade is correlated with smoking amount and dura-
ion. Tumors in heavy smokers or current smokers tend to be
ess differentiated and more aggressive. It has been observed
hat smoking is associated with shortened lung cancer survival
ndependent of smoking-related comorbidities and other fac-
ors,25 and a beneficial effect from long-term cigarette smoking
essation for longer survival is observed for women patients
ith NSCLC.4 Smoking might affect lung cancer survival
hrough modifying tumor genetic make-up and affecting tumor
ifferentiation.
The variables included in the risk adjustment for histologic
rade in the study are those more frequently implicated in the
iterature for NSCLC prognosis. Other factors such as perfor-
ance status, comorbidities, or other malignant diseases may
lay a role in affecting lung cancer survival and modify the risk
f histologic grade. To evaluate the potential effect, we added
erformance status, previous other cancer, chronic obstructive
ulmonary disease, other lung disease, diabetes, cardiovascular
isease, hypertension, and any other disease into our primary
odel and analyzed a subset of 2859 patients with complete
nformation on these additional variables. The results from this
xpanded model were almost identical to our original model.
nother concern is whether the traditional regression model is
dequate for confounding adjustment in an observational
tudy. To address the issue, we applied the preferred propen-
ity score method to our data and obtained the similar results
ith the traditional model-based adjustment. The supplemen-
ary results further support an independent association of his-
ologic grade with lung cancer survival, and it is less likely that
istologic grade is a surrogate of other factors.
In summary, histologic grade has important prognostic
alue for NSCLC as determined in two cohorts of patients with
xtensive follow-up data. The inconsistent results reported
reviously may be due to underpowered sample sizes or varied
atient populations. Histologic grade may provide useful in-
ormation in defining the aggressiveness of tumors, should be
onsidered as an independent factor affecting survival beyond
NM staging, and may offer guidance in patient management.
We thank Susan Ernst for her technical assistance with the
anuscript.
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